140 related articles for article (PubMed ID: 21575005)
1. Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation.
Hosing C; Smith V; Rhodes B; Walters K; Thompson R; Qazilbash M; Khouri I; de Lima M; Balzer RJ; McMannis J; Champlin R; Giralt S; Popat U
Transfusion; 2011 Jun; 51(6):1300-13. PubMed ID: 21575005
[TBL] [Abstract][Full Text] [Related]
2. Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma.
Gettys SC; Gulbis A; Wilhelm K; Sasaki K; Dinh Y; Rondon G; Qazilbash MH
Eur J Haematol; 2017 Apr; 98(4):388-392. PubMed ID: 28009447
[TBL] [Abstract][Full Text] [Related]
3. Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma.
Hill BT; Rybicki L; Smith S; Dean R; Kalaycio M; Pohlman B; Sweetenham J; Tench S; Sobecks R; Andresen S; Copelan E; Bolwell BJ
Leuk Lymphoma; 2011 Jun; 52(6):986-93. PubMed ID: 21314484
[TBL] [Abstract][Full Text] [Related]
4. Plerixafor to the rescue: boosting peripheral blood stem cell mobilization in patients previously treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone/methotrexate, cytarabine (Hyper-CVAD) chemotherapy.
Yuan S; Wang S; Salhotra A; Nademanee A
Leuk Lymphoma; 2014 Jul; 55(7):1557-62. PubMed ID: 24067136
[TBL] [Abstract][Full Text] [Related]
5. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
[TBL] [Abstract][Full Text] [Related]
6. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation.
Xia W; Ma CK; Reid C; Bai L; Wong K; Kerridge I; Ward C; Greenwood M
J Clin Apher; 2014 Dec; 29(6):322-30. PubMed ID: 24944079
[TBL] [Abstract][Full Text] [Related]
7. High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving Survival of Lymphoma.
Hyun SY; Cheong JW; Kim SJ; Min YH; Yang DH; Ahn JS; Lee WS; Ryoo HM; Do YR; Lee HS; Lee JH; Oh SY; Suh C; Yhim HY; Kim JS
Biol Blood Marrow Transplant; 2014 Jan; 20(1):73-9. PubMed ID: 24141009
[TBL] [Abstract][Full Text] [Related]
8. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
Pusic I; Jiang SY; Landua S; Uy GL; Rettig MP; Cashen AF; Westervelt P; Vij R; Abboud CN; Stockerl-Goldstein KE; Sempek DS; Smith AL; DiPersio JF
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768
[TBL] [Abstract][Full Text] [Related]
9. Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.
Sheppard D; Tay J; Palmer D; Xenocostas A; Doulaverakis C; Huebsch L; McDiarmid S; Tinmouth A; Mallick R; Martin L; Birch P; Hamelin L; Allan D; Bredeson C
Biol Blood Marrow Transplant; 2016 Apr; 22(4):763-767. PubMed ID: 26643030
[TBL] [Abstract][Full Text] [Related]
10. The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation.
Jeon SY; Yhim HY; Kim HS; Kim JA; Yang DH; Kwak JY
Korean J Intern Med; 2018 Nov; 33(6):1169-1181. PubMed ID: 29295612
[TBL] [Abstract][Full Text] [Related]
11. Stem cell mobilization in multiple myeloma patients relapsing after previous autologous hematopoietic stem cell transplantation: A multicenter report by the Polish Myeloma Study Group.
Drozd-Sokołowska J; Waszczuk-Gajda A; Topczewska M; Mańko J; Hus I; Szmigielska-Kapłon A; Nowicki M; Grygoruk-Wiśniowska I; Krawczyk-Kuliś M; Romejko-Jarosińska J; Frączak E; Wróbel T; Piątkowska-Jakubas B; Mądry K; Boguradzki P; Król M; Kozioł M; Hus M; Kopińska A; Dmoszyńska A; Basak GW; Dwilewicz-Trojaczek J
J Clin Apher; 2021 Jun; 36(3):443-453. PubMed ID: 33592119
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas.
Zhou P; Liu P; Zhou SY; He XH; Han XH; Qin Y; Yang S; Zhang CG; Gui L; Yao JR; Zhao LY; Zhang SX; Sun Y; Shi YK
Chin Med J (Engl); 2015 Sep; 128(18):2498-504. PubMed ID: 26365969
[TBL] [Abstract][Full Text] [Related]
14. Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients.
Nowrousian MR; Waschke S; Bojko P; Welt A; Schuett P; Ebeling P; Flasshove M; Moritz T; Schuette J; Seeber S
Ann Oncol; 2003; 14 Suppl 1():i29-36. PubMed ID: 12736228
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and Safety of Etoposide Combined with Cyclophosphamide for Autologous Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma].
Tu ST; Zhou YL; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1410-1414. PubMed ID: 37846692
[TBL] [Abstract][Full Text] [Related]
16. Chemomobilization with Etoposide is Highly Effective in Patients with Multiple Myeloma and Overcomes the Effects of Age and Prior Therapy.
Wood WA; Whitley J; Moore D; Sharf A; Irons R; Rao K; Serody J; Coghill J; Gabriel D; Shea T
Biol Blood Marrow Transplant; 2011 Jan; 17(1):141-6. PubMed ID: 20637882
[TBL] [Abstract][Full Text] [Related]
17. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
Popat U; Saliba R; Thandi R; Hosing C; Qazilbash M; Anderlini P; Shpall E; McMannis J; Körbling M; Alousi A; Andersson B; Nieto Y; Kebriaei P; Khouri I; de Lima M; Weber D; Thomas S; Wang M; Jones R; Champlin R; Giralt S
Biol Blood Marrow Transplant; 2009 Jun; 15(6):718-23. PubMed ID: 19450756
[TBL] [Abstract][Full Text] [Related]
18. Effective chemomobilization with etoposide and cytarabine (EC regimen) in lymphoma patients: a single-center, retrospective, observational study.
Koyama D; Nishiwaki S; Harada Y; Yamamoto S; Kurahashi S; Sugimoto T; Iwasaki T; Sugiura I
Jpn J Clin Oncol; 2017 Sep; 47(9):820-825. PubMed ID: 28541555
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myeloma.
Heider M; Grass S; Dill V; Rämisch S; Winter C; Verbeek M; Götze KS; Bassermann F; Jilg S
Transfus Apher Sci; 2021 Oct; 60(5):103197. PubMed ID: 34175195
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Various Hematopoietic Stem Cell Mobilization Regimens in Patients with Lymphoma and Myeloma.
Yilmaz Ü; Salim O; Yücel OK; Iltar U; Ündar L
Clin Lab; 2019 Oct; 65(10):. PubMed ID: 31625348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
